<DOC>
	<DOC>NCT00617695</DOC>
	<brief_summary>The purpose of this study is to evaluate the effectiveness and safety of Zolmitriptan (Zomig) nasal spray, 5.0 mg, compared with placebo (inactive drug) for 2 migraine headaches over a 3-month period in adolescent patients (aged 12 to 17 years) with migraine headaches</brief_summary>
	<brief_title>Efficacy of Zolmitriptan (Zomig) in the Treatment of Migraines in Adolescents</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Zolmitriptan</mesh_term>
	<mesh_term>Oxazolidinones</mesh_term>
	<criteria>Adolescents aged 1217 years at the time of screening. Patients must not be enrolled if they will turn 18 years of age within 12 weeks after randomization. An established diagnosis of migraine for at least 1 year; a minimum of 2 migraines, considered to be moderately/severely disabling, per month on average during the school year A history of usual migraine duration of &gt;2hours untreated for the 3 month prior to screening A history of basilar, ophthalmoplegic or hemiplegic migraine headache or any potentially serious neurological condition that is associated with headache or clinically significant abnormalities indicated from the medical history, physical exam etc Has used monoamine oxidase inhibitorA (MAOA), methysergide, methylergonovine or cimetidine in the 2 weeks before randomization. Evidence of ischemic heart disease, arrhythmia, accessory conduction pathway disorder as determined by central cardiologist using predetermined and agreed upon pediatric standards; Has uncontrolled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Zolmitriptan</keyword>
	<keyword>ZOMIG</keyword>
	<keyword>migraine</keyword>
	<keyword>headache response</keyword>
	<keyword>headache</keyword>
	<keyword>headache pain</keyword>
</DOC>